Document:

Research and Development Agreement

 Exhibit 10.8 
  
 

 
  

 ** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. 
  
 RESEARCH AND DEVELOPMENT AGREEMENT 
  
 THIS
RESEARCH AND DEVELOPMENT AGREEMENT (this “Agreement”) is made as of the 20th day of June, 2003, by and between FORMULATION TECHNOLOGIES L.L.C., d/b/a PharmaForm, with an office located at 1006 Yeager Lane, Bldg. D,
Suite 101, Austin TX 78753 (“PharmaForm”), and AUXILIUM PHARMACEUTICALS, INC. with an office located at 160 W. Germantown Pike, Norristown, PA 19401 (“AUXILIUM”). 
  
 RECITALS 
  
 WHEREAS, AUXILIUM is engaged in the research, development and sale of pharmaceutical products; and

  
 WHEREAS, PharmaForm is in the business of and has
appropriate facilities for providing certain services to the pharmaceutical industry and others; and 
  
 WHEREAS, AUXILIUM and PharmaForm wish to enter into this Agreement for PharmaForm to provide certain services (the “Services”) to
AUXILIUM; 
  
 AGREEMENT 
  
 NOW, THEREFORE, for good and valuable consideration, AND INTENDING
TO BE LEGALLY BOUND, PharmaForm and AUXILIUM hereby agree as follows: 
  
 1. Duties and Responsibilities of PharmaForm 
  

	 	1.1.	This Agreement sets forth the general terms and conditions with respect to the Services. The description and payment schedule for the Services are expressly set forth in the
Exhibit(s) attached to this Agreement, which are incorporated by reference herein. 

  

	 	1.2.	PharmaForm agrees to provide the Services in accordance with: (a) all applicable state and federal laws and regulations, including, without limitation, the federal Food, Drug and
Cosmetics Act and standards of Good Clinical Practices, Good Laboratory Practices and Good Manufacturing Practices, as applicable; and (b) the standards and practices that are 

  
 CONFIDENTIAL 
 ** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. 
  

 

 
  

 generally accepted in the industry and exercised by other persons engaged in performing similar
services. 
  

	 	1.3.	The research and development work described in this Agreement shall be conducted at PharmaForm’s Food and Drug Administration (“FDA”) registered facility and
PharmaForm will have the appropriate permits from the DEA and local drug enforcement authorities to work with scheduled substances at all times during the term of this Agreement. 

  
 2. Conflicts of Interest 
  

	 	2.1.	PharmaForm represents and warrants that PharmaForm is authorized to enter into this Agreement and that the terms of this Agreement are not inconsistent with or a violation of any
contractual or other legal obligation to which PharmaForm is subject. 

  

	 	2.2.	The parties agree and acknowledge that PharmaForm is in the business of providing contract research and development services to the pharmaceutical industry. Accordingly, PharmaForm
shall be free to undertake the provision of services to any third-party and/or conduct research and development on its own behalf so long as it does not develop products that compete directly with products developed for AUXILIUM or otherwise breach
the confidentiality and intellectual property provisions of this Agreement; provided that PharmaForm shall not be precluded from performing manufacturing or analytical services on a contract basis. 

  
 3. Confidentiality 
  

	 	3.1.	“Confidential Information” shall mean any and all information, including but not limited to, clinical, analytical and/or scientific data, reports, processes,
procedures, methods, formulations, inventions, and/or trade secrets relating to products developed pursuant to this Agreement and any other non-public information disclosed by a party (the “Disclosing Party”) to the other party (the
“Receiving Party”) pursuant to this Agreement of any kind, nature or description concerning any matters affecting or relating to the business of the Receiving Party. Confidential Information also includes, but is not limited to,
trade secrets, ideas, inventions, research and development work, work-in-process, products, methods, procedures, technology, computer software, databases and programming, test data and data files, know-how, designs, specifications, programs,
standard operating procedures, policies, guidelines, processes, formulations and unpublished data, personnel, staffing, cost, profit, marketing, sales, engineering and manufacturing data and information, patient, customer, supplier and investigator
lists and data, and proposals and contracts (including specifically this Agreement), salary structure/compensation information, pricing strategies, budgets and other related data, financial information and projections, services, techniques and any
other 

  
 CONFIDENTIAL 
 ** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT
REQUEST. 
  

 -2- 

 

 
  

 information which, if divulged to a third-party, could have an adverse impact on the Disclosing
Party, or on any third-party to which such Disclosing Party owes a confidentiality obligation. However, Confidential Information shall not include information that (i) is or becomes generally publicly available through no fault of a party to this
Agreement; (ii) the Receiving Party can prove was known to the Receiving Party prior to the disclosure of the information by the Disclosing Party; or (iii) is required to be disclosed by court order or applicable law, provided that the Receiving
Party shall use its best efforts to limit such disclosure and to obtain confidential treatment or a protective order for such Confidential Information. 
  

	 	3.2.	Each party agrees that it shall not at any time, whether during or after the termination of this Agreement (a) use any Confidential Information of a Disclosing Party for any purpose
other than performing obligations pursuant to this Agreement and the Exhibit(s); or (b) disclose or otherwise make available, directly or indirectly, any item of Confidential Information to anyone other than those of the Receiving Party’s
employees, independent contractors or agents who reasonably need to know the same in the performance of the obligations under this Agreement and the Exhibit(s). Each party shall advise its employees, independent contractors and agents who have
access to any Confidential Information of the confidential nature thereof, and agrees that such persons will be bound by terms of confidentiality with respect thereto that are at least as restrictive as the terms of this Section 3.

  

	 	3.3.	Upon the completion or earlier termination of this Agreement, or at any time upon request, a Receiving Party shall promptly return to the Disclosing Party all written Confidential
Information. 

  
 4. Independent Contractor 

 

	 	4.1.	The parties acknowledge that PharmaForm is an independent contractor and agrees that: 

  

	 	(a)	PharmaForm has an independently established business and is engaged by AUXILIUM to undertake the Services for a limited period of time; 

  

	 	(b)	Nothing in this Agreement shall be construed to create a partnership, joint venture, employment or similar relationship between PharmaForm and AUXILIUM; 

  
 5. Intellectual Property 
  

	 	5.1.	If at any time or times during the term of this Agreement, PharmaForm shall (either alone or with others), make, conceive, create, discover, invent or reduce to practice any
invention, modification, discovery, design, development, improvement, process, software program, work of authorship, documentation, formula or data (collectively, “Developments”), whether 

  
 CONFIDENTIAL 
 ** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. 
  

 -3- 

 

 
  

 or not patentable or registrable under any patent, copyright, trademark or similar statutes or
subject to analogous protection (collectively, “Legal Protection”) that (a) relate to PharmaForm’s work with or business of AUXILIUM (including, without limitation, any of the products or services being or to be developed,
manufactured or sold by AUXILIUM), (b) result from the performance of the Services, (c) result from the use of premises or personal property (whether tangible or intangible) owned, leased or contracted for by AUXILIUM, or (d) result from or are
based on Confidential Information of AUXILIUM, such Developments, and any rights that PharmaForm may have or acquire therein in any country throughout the world, and their resulting benefits (collectively, “Rights”) are and shall
immediately become the sole and absolute property of AUXILIUM, as “work made for hire” or otherwise; provided, however, nothing here shall (i) give AUXILIUM any Rights in the intellectual property of PharmaForm existing prior
to this Agreement or otherwise unrelated to this Agreement; or (ii) affect the rights set forth in the license agreement entered into by and between AUXILIUM and PharmaForm dated the same date hereof. 
  

	 	5.2.	PharmaForm hereby assigns to AUXILIUM, without further compensation at any time, all of PharmaForm’s Rights with respect to the Developments. To ensure AUXILIUM’s
ownership of the Developments, PharmaForm shall promptly: 

  

	 	(a)	Disclose each Development to AUXILIUM (or any persons designated by it), and without disclosing the same to others, communicate to AUXILIUM all available information relating to the
Developments (with all necessary plans and models); and 

  

	 	(b)	Whether during or after the termination of this Agreement, at the reasonable request and cost of AUXILIUM, sign, execute, make and do all such deeds, documents, acts and things as
AUXILIUM and its duly authorized agents may reasonably require to (i) apply for, obtain, register, vest, renew and restore, in the name of AUXILIUM alone (unless AUXILIUM otherwise directs), any Rights with respect to the Developments under Legal
Protection in any country throughout the world; and (ii) enforce and defend any judicial, opposition or other proceedings, petitions or applications in respect of such Legal Protection relating to a Development, or the revocation thereof.

  

	6.	PharmaForm Warranties 

  

	 	6.1	PharmaForm represents and warrants that PharmaForm has never been and is not currently: 

  

	 	(a)	An individual who has been debarred or convicted of a crime for which a person can be debarred by the U.S. Food and Drug Administration (the “FDA”) under 21 U.S.C.
§335a (a) or (b), or by any other regulatory agency (a “Debarred Individual”), from providing services in any capacity to a person or entity that has an approved or pending 

  
 CONFIDENTIAL 
 ** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. 
  

 -4- 

 

 
  

 drug product application, or an employer, employee or partner of a Debarred Individual; or

  

	 	(b)	A corporation, partnership, or association that has been debarred by the FDA under 21 U.S.C. §335a (a) or (b), or by any other regulatory agency (a “Debarred
Entity”), from submitting or assisting in the submission of an abbreviated new drug application, or an employee, partner, shareholder, member, subsidiary or affiliate of a Debarred Entity. 

  

	 	6.2	PharmaForm further represents and warrants that PharmaForm has not been convicted of or pled guilty or no contest to a crime or been sanctioned by a federal or state law
enforcement, regulatory, or licensing agency. 

  

	 	6.3	PharmaForm further represents and warrants that PharmaForm has no knowledge of any circumstances which may affect the accuracy of the representations set forth in Sections 6.1 or
6.2, and that PharmaForm will immediately notify AUXILIUM in the event of any such debarment, conviction, threat or indictment occurring during the term of this Agreement. 

  

	 	6.4	PharmaForm warrants that PharmaForm will comply with all applicable requirements of the Health Insurance Portability and Accountability Act, 45 CFR§160 et seq.
(“HIPAA”) relating to the use and or disclosure of Protected Health Information as defined in 45 CFR§ 160.501. 

  

	 	6.5	PharmaForm DISCLAIMS ALL WARRANTIES EXCEPT THOSE SET FORTH IN THIS PARAGRAPH, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMIMTATION, IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS
FOR A PARTICULAR PURPOSE. 

  
 7. Restrictions on
Announcements 
  
 PharmaForm shall not make any announcement, oral
presentation or publication relating to the Services without AUXILIUM’s prior written consent, except as required by law or by court or administrative order, provided however, that prior written notice is provided to AUXILIUM and
that AUXILIUM has the opportunity to appeal such requirement. PharmaForm shall not employ or use the name of AUXILIUM in any publication or promotional material or in any form for public distribution, without the prior written consent of AUXILIUM.

  
 8. FDA Inspection 
  
 In the event that PharmaForm receives a Notice of Inspection (a “Notice”)
from the Food and Drug Administration (“FDA”) which relates to the Services, PharmaForm shall: (a) notify AUXILIUM 
  
 CONFIDENTIAL 
 ** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED
AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. 
  

 -5- 

 

 
  

 promptly of such Notice; (b) keep AUXILIUM informed of the progress of the inspection; and (c) provide to AUXILIUM a
copy of any documents produced to the FDA pursuant to such Notice. AUXILIUM acknowledges that it is PharmaForm’s obligation to respond to a Notice directed to PharmaForm that PharmaForm must respond to the Notice without advice from, or
consultation with, AUXILIUM concerning the contents thereof. 
  
 9. Access
to Facilities 
  
 AUXILIUM’s authorized representatives may visit
PharmaForm’s site and facilities at reasonable times and with reasonable frequency during normal business hours and upon reasonable advance written notice. 
  

10. Termination 
  

	 	10.1	Either party may terminate this Agreement and/or any Exhibit at any time and for any reason upon a minimum of thirty (30) days’ prior notice to the other party. In the event of
any such early termination of some or all of the Services, each party shall assemble and turn over in an orderly fashion to authorized representatives of the other party all documents, write-ups, notes, computer programs and other material related
thereto, and AUXILIUM shall pay the charges stated herein for Services satisfactorily performed for the period since the date of commencement of the Services through the date of notice of termination. 

  

	 	10.2	Either party shall have the right at any time to cancel this Agreement and/or the Exhibit(s) immediately for non-performance or material breach of this Agreement or such Exhibit(s)
by the other party; provided, however, that no such termination of this Agreement shall relieve a breaching party of any liability or obligation it might otherwise have. 

  
 11. Equitable Relief 
  
 Both parties agree that any breach of Sections 2, 3 or 5 of this
Agreement will cause irreparable damage to the other party and that in the event of such breach, each party shall have, in addition to any and all remedies at law, the right to an injunction, specific performance or other equitable relief to prevent
the violation of PharmaForm’s obligations hereunder. 
  

	12.	Indemnification 

  

	 	12.1	AUXILIUM agrees to indemnify, defend and hold harmless PharmaForm from and against any and all claims, demands, investigations, suits or actions, (each a “Claim”)
for any and all liability, losses, damages, costs or expenses (including reasonable 

  
 CONFIDENTIAL 
 ** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. 
  

 -6- 

 

 
  

 attorneys’ fees and costs of court) arising out of or related to the Services performed pursuant
to this Agreement, including without limitation any and all claims of patent infringement that may be brought against PharmaForm related to exploitation or use of the Developments; provided, however, that AUXILIUM’s indemnity obligations shall
not apply to any Claim arising directly from the gross negligence, bad faith or willful misconduct of PharmaForm; a material breach of any applicable federal, state or local law by PharmaForm; or a material breach of this Agreement by PharmaForm.

  
 12.2 PharmaForm agrees to indemnify, defend and hold harmless
AUXILIUM and each of its affiliates, officers, directors, employees and representatives from any against and all Claims for liability, losses, damages, costs or expenses (including reasonable attorneys’ fees and costs of court) arising out of
or related to the gross negligence, bad faith or willful misconduct on the part of PharmaForm; or a breach of any applicable federal, state or local law by PharmaForm; or a material breach of this Agreement by PharmaForm. 
  
 12.3 Each party’s agreement to indemnify and hold the other harmless is
conditioned on the indemnified party: providing written notice to the indemnifying party of any claim, demand or action arising out of the Indemnified activities as soon as practicable but at least within thirty (30) days after the indemnified party
receives written notice of such claim, demand or action; permitting the indemnifying party to assume full responsibility to investigate, prepare for and defend against any such claim or demand; assisting the indemnifying party at the indemnifying
party’s reasonable expense, in the investigation of, preparation for and defense of any such claim or demand; and not compromising or settling such claim or demand without the indemnifying party’s written consent. 
  
 13. Limitations 
  

	 	13.1	BOTH PARTIES EXPRESSLY AGREE THAT EXCEPT WITH RESPECT TO CLAIMS ARISING OUT OF FRAUD, INTENTIONAL MISCONDUCT AND/OR FAILURE TO COMPLY WITH OBLIGATIONS OF CONFIDENTIALITY PURSUANT TO
PARAGRAPH 3 OF THIS AGREEMENT, NEITHER PARTY SHALL BE LIABLE OR RESPONSIBLE TO THE OTHER PARTY FOR ANY INCIDENTAL, INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES WHATSOEVER, INCLUDING, BUT NOT LIMITED TO, LOST PROFITS AND DAMAGES RESULTING FROM LOSS OR
USE OR LOSS OF CORRPUTED DATA OR SOFTWARE, EVEN IF SUCH PARTY HAS BEEN ADVISED, KNEW OF OR SHOULD HAVE KNOWN OF THE POSSIBILITY THEREOF. EXCEPT WITH RESPECT TO CLAIMS ARISING OUT OF FRAUD, INTENTIONAL MISCONDUCT AND/OR FAILURE TO COMPLY WITH
OBLIGATIONS OF 

  
 CONFIDENTIAL 
 ** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT
REQUEST. 
  

 -7- 

 

 
  

 CONFIDENTIALITY PURSUANT TO PARAGRAPH 3 OF THIS AGREEMENT, PHARMAFORM SHALL NOT BE LIABLE TO AUXILIUM
FOR ANY AMOUNT GREATER THAN THE AGGREGATE OF ALL PAYMENTS RECEIVED BY PHARMAFORM FROM AUXILIUM UNDER THIS AGREEMENT. 
  

	 	13.2	PharmaForm agrees to use its best efforts to accomplish the agreed goals with AUXILIUM, but nothing herein shall bind PharmaForm to any guarantees of success at any development
stage and absent a showing of gross negligence or willful misconduct, PharmaForm shall have no liability under this Agreement or otherwise for any failure to achieve the goals set forth in the Project Plan. 

  
 14. Entire Agreement 
  
 This Agreement, together with all corresponding Exhibits, constitutes the entire agreement
between the parties with respect to the subject matter hereof, and supersedes any and all prior and contemporaneous communications, representations, agreements or understandings, whether oral or written. No amendment or modification of this
Agreement or any Exhibit shall be binding unless in a writing signed by both parties. 
  
 15. Construction of Agreement 
  
 The failure of either
party to enforce any provision of this Agreement shall not be construed as a waiver or limitation of that party’s right to subsequently enforce and compel strict compliance with every provision of this Agreement. If any provision of this
Agreement or the application thereof shall be invalid or unenforceable, the remainder of this Agreement shall be unaffected thereby and each remaining term or provision of this Agreement shall be valid and be enforced to the fullest extent permitted
by law. This Agreement shall be governed by and construed in accordance with the laws of the State of Texas, without regard to provisions of conflicts of law. 
  

16. Assignment 
  
 Neither PharmaForm nor AUXILIUM may assign this Agreement or any rights hereunder or delegate the performance of any duties hereunder without the prior written approval
of the other party, which approval shall not be unreasonably delayed or withheld; provided, however, that without such consent, AUXILIUM may assign this Agreement to an affiliate or in connection with the transfer or sale of all or
substantially all of its assets, stock or business, or its merger, consolidation or combination with or into another entity. Subject to the foregoing, this Agreement shall be binding upon, inure to the benefit of and be enforceable by the respective
heirs, administrators, successors and permitted assigns of the parties. 
  
 CONFIDENTIAL 
 ** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. 
  

 -8- 

 

 
  

 17. Survival 
  

Any terms of this Agreement which by their nature extend beyond its performance, expiration or termination (including, without limitation, Sections 3, 5,
11 and this Section 17) shall survive any termination or expiration of this Agreement, however caused. 
  

	18.	Notices 

  
 Any notices given under this Agreement shall be in writing and shall be given by personal delivery, or sent by (a) facsimile transmission (with message confirmed during normal business hours); (b) first class mail,
postage prepaid; or (c) Federal Express (or equivalent overnight delivery service), delivery charges prepaid. All notices shall be given to a party at its respective address set forth in this agreement, or at such other address as such party may
specify by notice in accordance with this Section 18. A notice shall be deemed given when actually received. 
  
 19. Dispute Resolution. Except as otherwise specifically provided herein, any disputes or disagreements arising under the Agreement will be referred to the chief executive officer of each party for a
period not to exceed sixty (60) days. During such sixty (60) days, both parties may in good faith explore resolution of the dispute using alternative dispute resolution techniques before pursuing other remedies. If such dispute is not resolved by
the end of such sixty-day period, the parties shall be free to pursue any legal or equitable remedy available to them. 
  
 CONFIDENTIAL 
 ** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED
AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. 
  

 -9- 

 

 
  

 20. Signatories 
  
 This Agreement may be executed in counterparts, each of which, when executed and delivered, shall be deemed to be an original, and all of
which, when joined, shall together constitute one and the same agreement. Any photocopy or facsimile of this Agreement, or of any counterpart, shall be deemed the equivalent of an original. 
  
 ACCEPTED AND APPROVED BY AND BETWEEN: 
  

									
	Formulation Technologies L.L.C., d/b/a PharmaForm	 	 	 	AUXILIUM PHARMACEUTICALS, INC.
					
	 By:
	 	 /s/    Robert O. Williams, III
	 	 	 	 By:
	 	 /s/    Geraldine A.
Henwood        

	 Print Name:
	 	Robert O. Williams, III	 	 	 	 Name:
	 	Geraldine A. Henwood
	 Title:
	 	 Vice Pres.

	 	 	 	 Title:
	 	 CEO

  
 CONFIDENTIAL 
 ** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT
REQUEST. 
  

 -10- 

 

 
  

 EXHIBIT 1 TO RESEARCH AND DEVELOPMENT AGREEMENT BETWEEN 
 FORMULATION TECHNOLOGIES L.L.C., D/B/A PharmaForm AND AUXILIUM 
 PHARMACEUTICALS, INC., DATED JUNE 20, 2003 
  

	1.	SERVICES TO BE PERFORMED 

  
 Satisfactory completion of the following services shall be provided by PharmaForm and may not be replaced without the prior written consent of AUXILIUM:

  

	 	(a)	The services included on the attached Project Plan (the “Services”) shall be performed by PharmaForm in consultation with AUXILIUM, based on the timelines included
in the Project Plan, for the following projects: 

  

	 	•	Androgens (Project 1); 

  

	 	•	Oxybutynin (Project 2). 

  

	2.	PAYMENT FOR PERFORMANCE OF SERVICES 

  
 In consideration of the Services, AUXILIUM shall pay PharmaForm $[**] per month, per project which monthly fee shall include the cost
of all materials and supplies, exclusive of the respective active pharmaceutical ingredients (“APIs”). 
  
 Auxilium shall make a start-up payment of $[**], covering the first three months of Services, on June 20, 2003. Thereafter,
PharmaForm will submit invoices for Services performed on a monthly basis. 
  

	3.	TERMS AND CONDITIONS 

  
 All other terms and conditions of the Research and Development Agreement dated June 20, 2003 are incorporated by reference as if fully set forth
herein. 
  
 EXHIBIT ACCEPTED AND APPROVED BY AND BETWEEN: 
  

							
	FORMULATION TECHNOLOGIES L.C.C. d/b/a PharmaForm	 	AUXILIUM PHARMACEUTICALS, INC.
				
	 By:
	  	 /s/    Robert O. Williams, III
	 	 By:
	  	 /s/    Geraldine A. Henwood        

  
 CONFIDENTIAL 
 ** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT
REQUEST. 
  

 

 
  

							
				
	 Print Name:
	  	 Robert O. Williams, III
	 	 Name:
	  	 Geraldine A. Henwood

	 	  	
	 	 	  	

	 Title:    Vice Pres.
	 	 Title:
	  	 CEO

			
	 Date:    6-20-03
	 	 Date:
	  	 6-23-03

  
 CONFIDENTIAL 
 ** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT
REQUEST. 
  

 -2-Commercial Outsourcing Services Agreement

 Exhibit 10.12 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  
 COMMERCIAL OUTSOURCING SERVICES AGREEMENT

  
 This Commercial Outsourcing Services Agreement
(“Agreement”) is entered into as of November 13, 2002 (“Effective Date”) by and between Integrated Commercialization Solutions, Inc., a California corporation (“Service Provider”) and Auxilium Pharmaceuticals, Inc., a
Delaware corporation (“Company”). 
  
 RECITALS

  
 A. Company is, among other things, in the business of
manufacturing or having manufactured, selling and distributing pharmaceutical products, including those listed on Schedule A (“Products”). 
  
 B. Service Provider is in the business of, among other things, providing commercialization services. 
  
 C. Company desires to engage Service Provider as its agent to provide certain
commercialization services related to the Products upon the terms and subject to the conditions set forth in this Agreement. 
  
 D. Service Provider desires to provide such commercialization services to Company as its agent upon the terms and subject to the conditions set forth in
this Agreement. Capitalized words used without definition in this Agreement will each have the meaning in Appendix A. 
  
 AGREEMENT 
  
 NOW, THEREFORE, in consideration of the mutual covenants contained herein, the above recitals and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties, intending to be legally bound, hereby agree as follows: 
  

	1.	APPOINTMENT AS EXCLUSIVE AGENT 

  
 Company hereby appoints Service Provider as its exclusive outsourcing supplier for warehousing and distributing Products to be sold in the United States,
Guam, Puerto Rico and the U.S. Territories during the Term (as defined in Section 4.1) subject to the provisions of this Agreement; provided, however, if Service Provider cannot meet Company’s demand for warehousing and distributing Products,
Company may engage a third party to supply those services Service Provider cannot provide pursuant to this Agreement. 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  

 1 

	2.	SERVICES TO BE PERFORMED 

  
 Company hereby engages Service Provider to provide the following services (“Services”): 
  

	 	2.1	Integrated Access Center as set forth in Exhibit B. 

  

	 	2.2	Order Process Management as set forth in Exhibit C. 

  

	 	2.3	Warehousing and Inventory Program as set forth in Exhibit D. 

  

	 	2.4	Distribution Services as set forth in Exhibit E. 

  

	 	2.5	Contract Management and Chargebacks as set forth in Exhibit H. 

  

	 	2.6	Accounts Receivable Management and Cash Applications as set forth in Exhibit I. 

  

	 	2.7	Finance Management as set forth in Exhibit J. 

  

	 	2.8	Information Technology Service as set forth in Exhibit K. 

  

	3.	COMPENSATION—FEES FOR SERVICES 

  
 Company shall compensate Service Provider for all services provided hereunder in accordance with Schedule B. Payment is due net thirty (30) days
from the invoice date. A late fee of 1.5% per month (or part of a month) will be charged on all amounts not paid within sixty (60) days of the date of the invoice date, except for any portion of any bill that is the subject of any dispute raised by
Company in good faith. Service Provider will bill Company for any pass through charges monthly or as Service Provider is billed. All other fees for Services will be billed monthly. 
  

	4.	TERM AND TERMINATION 

  
 4.1 Initial Term. This Agreement shall be effective as of the Effective Date and shall continue in full force and effect thereafter for a period of
three (3) years from the Effective Date (“Term”) unless sooner terminated as provided herein, and may be extended upon written mutual agreement of the parties, such extension to be negotiated in good faith six (6) months prior to the
expiration of the Term. 
  
 4.2 Termination Without Cause.
Notwithstanding anything to the contrary contained herein, either party may terminate this Agreement, with or without cause, at any time by providing the other party with at least one hundred eighty (180) days’ prior written notice of such
termination. 
  
 4.3 Termination For Breach. In addition to any
other termination rights contained herein, either party may terminate this Agreement upon written notice to the other party following such other party’s failure to cure a material breach of this Agreement within ten (10) 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  

 2 

 days after receipt of written notice of such breach. Such cure period shall be suspended for so long as the breaching
party has diligently commenced to cure such breach and continues diligently to complete such cure; provided, however such cure period may not exceed ninety (90) days. 
  
 4.4 Termination For Specific Events. Any party may terminate this Agreement immediately by providing the other
parties with concurrent written notice of such termination in the event that any other party: (a) commences a voluntary case or other proceeding seeking liquidation, reorganization or other relief with respect to its debts under any bankruptcy,
insolvency, or other similar law now or hereafter in effect; (b) makes a general assignment for the benefit of creditors; (c) becomes insolvent; (d) ceases doing business; and/or (e) takes any corporate action to authorize any of the foregoing. Each
party agrees to provide immediate notice to all other parties upon the occurrence of any event specified above. 
  
 4.5 Expenses. If Company executes its option under this Agreement to terminate without cause, it shall pay the reasonable and proper documented,
non-recoverable expenses related to telecommunication, facsimile, postage and shipping incurred by Service Provider for all services rendered in accordance with the terms of this Agreement. 
  
 4.6 Survival. All accrued payment, indemnity and confidentiality
obligations of the parties under this Agreement shall survive the termination of this Agreement and, except as provided elsewhere in this Agreement, termination of this Agreement shall not affect any obligations or liabilities arising, or based upon
acts or omissions occurring, prior to the date of such termination. 
  
 4.7 Return of Data and Information. Upon termination, Service Provider will promptly provide to Company all information and data relating to Products (“Product Data”) in a mutually agreeable form. Product Data includes all
Company Confidential Information and all information related to Products, shipping and tracking information, customer contact information, including customer names and current addresses, marketing and promotional materials and sales and marketing
information. Product Data does not include ICS Data (as defined in Section 8.3). 
  

	5.	RECALLS, OTHER REGULATORY ISSUES 

  
 5.1 If Company determines it to be necessary to conduct a recall, market withdrawal or field correction (a “Recall”) of any Products, Company
shall conduct, or designate a third party to conduct, the Recall, and Company shall incur all related expenses and have primary responsibility therefor. Service Provider shall cooperate with, and comply with all reasonable requests of, Company in
recalling any affected Products. To the extent a Recall was not due to Service Provider’s acts or omissions, then Company shall pay or reimburse, as the case may be, all of Service Provider’s documented direct out-of-pocket expenses
(including but not limited to any reasonable attorney’s fees and expenses) incurred by Service Provider in connection with any such Recall. To the extent a Recall was due to Service Provider’s acts or omissions, then Service Provider shall
pay or reimburse, as the case may be, all of Company’s expenses, including reasonable attorney’s fees, incurred in connection the Recall. Each of the parties shall use its best efforts to minimize the expenses of any Recall when it occurs.
Company shall use its 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  

 3 

 best efforts to inform Service Provider of any proposed Recall within forty-eight (48) hours of the initiation of the
Recall. 
  
 5.2 Each of the parties shall provide the other with a
copy of any correspondence or notices received by such party from the FDA (or counterpart state agency) or other regulatory agency specifically relating to services provided by Service Provider, pursuant to this Agreement, relating to a material
violation of any kind that is Company or Product related whether such violation resulted from an act or omission by the Company or by the Service Provider, or that otherwise affects Company’s Products or process no later than the next business
day following such receipt. In addition, Service Provider shall provide Company with all notices relating to the Products within two (2) business days of receipt thereof. Each party shall also provide the other with concurrent copies of any
responses to any such correspondence or notices (e.g., FDA 483 notice). Where reasonably possible, Service Provider shall give prior notice to Company of any scheduled FDA inspections of Service Provider’s facilities specifically relating to
any of the Products and, if reasonably possible, shall afford Company the opportunity to be present at such inspection and to review and contribute to any written response thereto to the extent permitted by law. 
  
 5.3 Service Provider and the Company where required, shall obtain and/or
maintain all required licenses in all states for the warehousing and shipping of the Products. Service Provider may collect sales tax, where applicable, in all states that Service Provider has registered for sales tax collection. In all other
states, Service Provider may collect all other sales taxes pursuant to the Company’s instructions and other legal requirements. 
  

	6.	LEGAL COMPLIANCE 

  
 6.1 During the Term of this Agreement, each party shall conduct its activities in connection with this Agreement in compliance with all applicable laws
and regulations. Specifically, Service Provider shall comply with all applicable Requirements of Law related to the storage, handling and distribution of Products, and Company shall comply with all applicable Requirements of Law related to the
importation, manufacture, distribution, labeling, storage, sale and handling of the Products. 
  
 6.2 Company agrees and does hereby represent and warrant to Service Provider during the Term of this Agreement that (a) all Products, and each shipment of each, or other delivery now and hereafter made by Company to
or on the order of Service Provider will not be, at the time of shipment or delivery, adulterated, misbranded or otherwise prohibited within the meaning of the Act or within the meaning of any applicable state or municipal law, (b) the Products are
not, at the time of shipment or delivery to Service Provider, merchandise which may not be introduced or delivered for introduction into interstate commerce under the provisions of Sections 404 or 405 of the Act, (c) all such Products will be the
subject of a duly approved NDA or ANDA and may be legally transported or sold under applicable Requirements of Law, and (d) all Product has been duly approved by all applicable Governmental Authority for commercial sale and shipment within the
United States. 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  

 4 

	7.	CORPORATE AUTHORITY 

  
 7.1 During the Term of this Agreement, Company represents and warrants to Service Provider that: (a) it has full power and authority to enter into this
Agreement and perform and observe all obligations and conditions to be performed or observed by it under this Agreement without any restriction by any other agreement or otherwise, (b) the execution, delivery and performance of this Agreement has
been duly authorized by all necessary corporate action, (c) this Agreement constitutes the legal, valid and binding obligation of Company, (d) no approvals, consents, orders or authorizations of or designation, registration, declaration or filing
with any Governmental Authority (within, as a part of, or constituting the United States of America) are required for the sale and distribution of the Product other than any such approvals obtained, (e) there is no action, proceeding, or
investigation pending or threatened which questions the validity of this Agreement, the marketing authorizations related to and for the Product, or any actions taken or to be taken pursuant to this Agreement, and (f) the Product, or any part
thereof, has not been materially adversely affected in any way as a result of any legislative or regulatory change, or any revocation of license or right to manufacture, distribute, handle, store, sell or market any of the Product. 
  
 7.2 During the Term of this Agreement, Service Provider represents and
warrants to Company that: (a) it has full power and authority to enter into this Agreement and perform and observe all obligations and conditions to be performed or observed by it under this Agreement without any restriction by any other agreement
or otherwise, (b) the execution, delivery and performance of this Agreement has been duly authorized by all necessary corporate action, (c) this Agreement constitutes the legal, valid and binding obligation of Service Provider, (d) no approvals,
consents, orders or authorizations of or designation, registration, declaration or filing with any Governmental Authority (within, as a part of, or constituting the United States of America) are required for the warehousing and distribution of
pharmaceutical products other than any such approvals obtained, (e) there is no action, proceeding, or investigation pending or threatened which questions the validity of this Agreement, Service Provider’s licenses to warehouse and distribute
pharmaceuticals, or any actions taken or to be taken pursuant to this Agreement, (f) the Product has not been materially adversely affected while in possession of the Service Provider as a result of any revocation of licenses or due to its breach of
its obligations hereunder and (g) in the event any of the representations and warranties contained herein become untrue at any time during the Term of this Agreement, Service Provider will immediately notify Company in writing. 
  
 7.3 Company and Service Provider shall give prompt written notice to the
other if such party becomes aware during the term of this agreement of any action or development which would cause any of said party’s warranties in this section to become untrue. 
  

	8.	TRADEMARKS, DATA & INTELLECTUAL PROPERTY 

  
 8.1 Neither party may use the name of any other party or the other party’s trademarks, service marks, logos, other similar marks or other
intellectual property (collectively “Trademarks”), or any data or information of the other party in any manner without the prior written approval of such other party. 
  
 8.2 Service Provider recognizes Company’s right, title and interest in Trademarks for Products or Company and may not
at any time do or cause to be done any act that would impair 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  

 5 

 Company’s property rights in such Trademarks. Service Provider may not acquire or claim any right, title, or
interest in such Trademarks. Use of such Trademarks will inure to Company’s benefit and Service Provider will execute any document Company requests to confirm Company’s rights to such Trademarks. 
  
 8.3 Neither party may use any data or information of the other party in any
manner without the other party’s prior written approval. Data and information that belongs to Company will be all Product Data and Company Confidential Information, except ICS Data. “ICS Data” includes Service Provider’s
Confidential Information and any information that is not specific to Products or is developed by Service Provider relating to the processes, reports and services provided by Service Provider to Company under this Agreement, including those relating
to any of Service Provider’s customers and their respective profiles. ICS Data belongs to Service Provider. 
  
 8.4 All concepts, inventions, improvements, ideas, patent rights, Trademarks and copyrights that relate to Products are exclusive property of Company,
except ICS Data. Concepts, inventions, improvements, ideas, patent rights, Trademarks and copyrights that have been developed independently of the Products and are not specific to Products or that relate to the processes, reports and services
developed by Service Provider will remain exclusive property of Service Provider. 
  

	9.	CONFIDENTIALITY 

  
 9.1 Each party acknowledges that as a result of this Agreement, each party may learn Confidential Information of the other party. None of the parties
shall disclose any Confidential Information of any other party to any person or entity, or use, or permit any person or entity to use, any of such confidential information, excepting only: (a) disclosures on a confidential basis to and use by the
directors, officers, employees, and agents of that party, or its affiliates, who have a reasonable need to know such information in connection with that party’s performance of this Agreement, and (b) disclosures to that party’s attorneys,
accountants, and other professional advisors in connection with matters relating to this Agreement. The specific material terms of this Agreement shall be deemed to be Confidential Information of each party. 
  
 9.2 The obligation of confidentiality hereunder shall survive the termination
of this Agreement for a period of five (5) years. 
  
 9.3 Upon
termination of this Agreement (for any reason) each party shall promptly: (a) return to the applicable party, all documentation and other materials (including copies of original documentation or other materials) containing any Confidential
Information of such party; or (b) certify to the applicable party, pursuant to a certificate in form and substance reasonably satisfactory to such party, as to the destruction of all such documentation and other materials. 
  

	10.	INDEMNIFICATION 

  
 10.1 Company shall defend, indemnify and hold harmless Service Provider and its Related Parties from and against all claims, liabilities, losses, damages,
costs and expenses, 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  

 6 

 including without limitation reasonable attorneys’ fees) (hereinafter collectively referred to as
“Claims”) brought by third parties and/or employees of Company against Service Provider and/or its Related Parties, as the case may be, caused by or arising out of: (a) any negligent or intentional act or omission of Company or its Related
Parties, (b) any failure of Company to perform and observe fully its obligations and conditions pursuant to this Agreement or to comply with relevant laws or regulations, (c) any breach of any warranty made by Company in this Agreement (d) Claims of
patent, trademark or copyright infringement related to the Products, (e) the storage and handling of the Products (other than by Service Provider or its Related Parties), or the use, non-use, demonstration, consumption, ingestion, digestion,
manufacture, production and assembly, of the Products and transportation to Service Provider, or (f) any liability assessments and penalties for Taxes that may be imposed against Service Provider or its Related Parties by any local, state, or
Federal taxing authority related to the Products (other than Taxes collected by Service Provider but not paid to such taxing authority); provided, however, that the Company shall have no indemnification or defense obligations under this Section 10.1
for any Claims to the extent they were caused by or arise out of the negligent or intentional act or omission of Service Provider or its Related Parties. 
  
 10.2 Service Provider shall defend, indemnify and hold harmless Company and/or its Related Parties from and against all Claims brought by third parties
and/or employees of Service Provider against Company and/or its Related Parties caused by or arising from (a) any negligent or intentional act or omission of Service Provider or its Related Parties, (b) any failure of Service Provider to perform and
observe fully its obligations pursuant to this Agreement or to comply with relevant laws or regulations, (c) storage or handling of the Products by Service Provider or its Related Parties, or (d) Service Provider’s making of representations and
warranties with respect to the Products not expressly authorized by Company; provided, however, that Service Provider shall have no indemnification or defense obligations under this Section 10.2 for any Claims to the extent they were caused by or
arise out of the negligent or intentional act or omission of Company or its Related Parties. 
  
 10.3 NOTWITHSTANDING THE FOREGOING OR ANY OTHER PROVISION TO THE CONTRARY CONTAINED IN THIS AGREEMENT, NONE OF THE PARTIES SHALL BE LIABLE TO ANY OTHER PARTY FOR ANY LOST PROFITS, CONSEQUENTIAL, INCIDENTAL,
INDIRECT, SPECIAL, OR OTHER SIMILAR DAMAGES ARISING OUT OF OR IN CONNECTION WITH A BREACH OF THIS AGREEMENT OR ANY EXPENSES, CHARGES, COSTS OR LIABILITIES, WHETHER FORESEEN OR UNFORESEEN, ARISING FROM OR RELATED TO THE USE OR PERFORMANCE OF THE
PRODUCTS OR PERFORMANCE OR TERMINATION OF THIS AGREEMENT EXCEPT THAT THIS LIMITATION SHALL NOT APPLY TO LIABILITY FOR CONSEQUENTIAL INCIDENTAL, INDIRECT OR SPECIAL DAMAGES ARISING OUT OF OR RELATING TO EITHER PARTY’S GROSS NEGLIGENCE OR
INTENTIONAL CONDUCT OR AS OTHERWISE EXPRESSLY PROVIDED HEREIN.  
  
 10.4 The obligations and liabilities of the parties with respect to Claims subject to indemnification under this Section 10, (“Indemnified Claims”), shall be subject to the following terms and conditions: 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  

 7 

 10.4.1 The party claiming a right to indemnification hereunder (the “Indemnified Person”) shall
give prompt written notice to the indemnifying party (the “Indemnifying Person”) of any Claim, stating the nature and basis of said Claim and the amount thereof to the extent known. Each such notice given hereunder shall be accompanied by
copies of all relevant documentation with respect to such Claim, including, without limitation, any summons, complaint or other pleading which may have been served or written demand or other document or instrument. 
  
 10.4.2 With respect to any Claim: (a) the Indemnifying Person shall defend or
settle the Claim, subject to the provisions of this subsection, (b) the Indemnified Person will, at the Indemnifying Person’s sole cost and expense, cooperate in the defense by providing access to witnesses and evidence available to it, or (c)
the Indemnified Person shall have the right to participate in any defense at its cost and expense to the extent that in its judgment the Indemnified Person may otherwise be prejudiced thereby. 
  
 10.4.3 Anything contained herein to the contrary notwithstanding, neither the
Indemnifying Person nor any of the Indemnified Persons shall admit any liability with respect to, settle, compromise or discharge or offer to settle, compromise or discharge, any Claim which is subject to indemnification under this Section 10
without the written consent of an officer of the other, which consent shall not be unreasonably withheld. In addition, each of the Indemnifying Person and the Indemnified Persons shall cooperate with, and comply with all reasonable requests of, each
other and act in a reasonable and good faith manner to minimize the scope of any Claim. 
  
 10.4.4 Notwithstanding anything to the contrary herein, and subject to the limitations of Section 10.3 herein, Service Provider shall not be liable to the Company for any damages (whether grounded in contract, tort,
or otherwise) arising under any Claim which is subject to indemnification under this Section 10 in an aggregate amount greater than all sums paid to Service Provider by the Company under this Agreement during the period of one (1) year prior to the
date upon which such claim(s) arose unless it is determined by a court of competent jurisdiction that Service Provider’s gross negligence or intentional misconduct was the primary cause of such Claim. 
  

	11.	INSURANCE 

  
 11.1 During the Term of this Agreement, Company will maintain: (a) casualty and theft or loss insurance in amounts sufficient to protect all Products and
other materials consigned to Service Provider, and (b) products liability and commercial general liability insurance having a limit of not less than five million dollars ($5,000,000.00), pursuant to one or more insurance policies with reputable
insurance carriers having a Best’s Rating of A VII or otherwise as reasonably approved by Service Provider. Company shall designate Service Provider and its parent corporations as “additional insureds” under all insurance policies
referenced in this Section. Company shall obtain a broad form Vendor’s endorsement for products liability for Service Provider, and its parent corporations. Within thirty (30) days after the date hereof, Company shall provide to Service
Provider a certificate of insurance indicating that such obligations have been satisfied. As a condition precedent to the effectiveness of this Agreement, Company shall execute the guarantee in the form of Exhibit A. 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  

 8 

 11.2 Service Provider shall, at its own expense, provide and keep in full force and effect during the
term of this Agreement the following kinds and minimum amounts of insurance: 
  
 (i) Workers’ Compensation. Workers’ compensation statutory coverage as required by the laws of the states in which the services hereunder are performed; 
  
 (ii) Employer’s Liability. Employer’s liability
insurance with a limit of $500,000 for bodily injury by accident per person, $500,000 for bodily injury by accident, all persons and $500,000 bodily injury by disease policy limit; 
  
 (iv) General Liability. Commercial general liability insurance, including personal injury blanket
contractual liability and broad form property damage, with a $1,000,000 combined single limit per occurrence; 
  
 (v) Errors and Omissions. Professional liability insurance covering the errors and omissions of Service Provider’s employees
providing professional or technical services (including but not limited to any negligence or willful misconduct of any member of the Service Provider Personnel in connection with their obligations set forth herein) of not less than $10,000,000 per
occurrence and aggregate; 
  
 (vi) Umbrella
Liability. Umbrella liability insurance in the amount of $5,000,000 per occurrence and aggregate; 
  
 (vii) Employer Practices Insurance. Employer practices insurance in the amount of $1,000,000 per occurrence; and 
  
 (viii) Property Insurance. Property insurance covering the
business property of Service Provider and others while at any unnamed location in the amount of $1,000,000; 
  
 11.3 Throughout the term of this Agreement, Service Provider shall have and maintain such policies in a form acceptable to Company and shall, within
thirty (30) days after the date of execution of this Agreement: make Company an additional insured under each of the foregoing policies; cause such policies to stipulate that the insurance will not be modified or cancelled while this Agreement is in
effect without thirty (30) days prior written notice to Company; and provide Company with proof of its compliance with this Section 11. 
  

	12.	NOTICES 

  
 Any notice or other communication required or desired to be given to any party under this Agreement shall be in writing and shall be deemed given: (a)
four (4) days after deposit in the United States mail, first-class certified, return receipt requested, and addressed to that party at the address for such party set forth at the end of this Agreement, (b) the next business day following timely
delivery to a reputable, national overnight delivery service for delivery to that 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  

 9 

 party at that address, or (c) upon receipt of electronic confirmation of delivery if sent by facsimile transmission to
that party at its facsimile numbers set forth at the end of this Agreement with hard copy sent by certified mail or overnight delivery in accordance with the terms of this Section. Any party may change its address or facsimile number for notices
under this Agreement by giving the other party written notice of such change in accordance with this Section. 
  

	13.	REMEDIES 

  
 With respect to the confidentiality provisions of this Agreement, each party acknowledges that in the event of any actual or threatened violation by that
party of any of such provisions, the other party may suffer irreparable harm and its remedies at law may be inadequate. Accordingly, in the event of any violation or attempted violation of any such provisions by either party, the other party shall
be entitled to petition for a temporary restraining order, preliminary and permanent injunctions, specific performance, and other equitable relief. The rights and remedies of each party under this Agreement shall be cumulative and in addition to any
other rights or remedies available to such party, whether under any other agreement, at law, or in equity. 
  

	14.	GOVERNING LAW 

  
 All questions concerning the validity or meaning of this Agreement or relating to the rights and obligations of the parties with respect to performance
under this Agreement shall be construed and resolved under the internal laws of the State of Delaware excluding its principles and provisions and body of law relating to conflicts or choice of laws. 
  

	15.	SEVERABILITY 

  
 The intention of the parties is to comply fully with all applicable Requirements of Law, and this Agreement shall be construed consistently with all
applicable Requirements of Law to the extent possible. If and to the extent that any court of competent jurisdiction determines that it is impossible to construe any provision of this Agreement consistently with any applicable Requirements of Law
and consequently holds that provision to be invalid, such holding shall in no way affect the validity of the other provisions of this Agreement, which shall remain in full force and effect. 
  

	16.	NON-WAIVER 

  
 No failure by either party to insist upon strict compliance with any term of this Agreement, to exercise any option, to enforce any right, or to seek any
remedy upon any default of the other party shall affect, or constitute a waiver of the first party’s right to insist upon strict compliance, to exercise that option, to enforce that right, or to seek that remedy with respect to that default or
any prior, contemporaneous, or subsequent default. No custom or practice of the parties at variance with any provision of this Agreement shall affect, or constitute a waiver of, that party’s right to demand strict compliance with all provisions
of this Agreement. 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  

 10 

	17.	FORCE MAJEURE 

  
 If the performance of any part of this Agreement by any of the parties shall be affected for any length of time by fire or other casualty, government
restrictions, war, riots, strikes or labor disputes, lock out, transportation delays, electronic disruptions, telecommunication failures, and acts of God, or any other causes which are beyond the control of the parties (financial inability
excepted), such party shall not be responsible for delay or failure of performance of this Agreement for such length of time, provided, however, (a) the affected party shall cooperate with and comply with all reasonable requests of the non-affected
party to facilitate the commercialization services to the extent possible, and (b) the obligation of one party to pay amounts due to any other party shall not be subject to the provisions of this Section. 
  

	18.	COUNTERPARTS 

  
 This Agreement may be executed simultaneously in two or more counterparts, each of which will be deemed to be an original, but all of which together will
constitute one instrument. 
  

	19.	HEADINGS 

  
 The headings of the various Sections of this Agreement are not part of the context of this Agreement, and are only labels to assist in locating those
Sections, and shall be ignored in construing this Agreement. 
  

	20.	COMPLETE AGREEMENT 

  
 This Agreement contains the entire agreement between the parties and supersedes all prior or contemporaneous discussions, negotiations, representations,
warranties, or agreements relating to the subject matter of this Agreement. No changes to this Agreement shall be made or be binding on either party unless made in writing and signed by both parties. All Schedules and Exhibits referred to in this
Agreement are incorporated by this reference. 
  

	21.	SUCCESSORS 

  
 Neither party may assign this Agreement or any of its rights or obligations under this Agreement without the prior written consent of the other party,
which consent shall not be unreasonably withheld. Notwithstanding the foregoing, without such consent, either party may assign this Agreement in connection with the transfer or sale of all or substantially all of its assets, stock or business, or
its merger, consolidation or combination with or into another entity; provided, however, that the assigning party remains liable for the assigned party’s performance and the assigned party demonstrates that it has the financial and other
ability to perform. Company hereby consents to Service Provider’s assigning part or all of its obligations to any affiliate and to assigning or granting a security interest in this Agreement in connection with any financing or securitization by
Service Provider or any affiliate. Subject to the foregoing, this Agreement shall be binding upon, inure to the benefit of and be enforceable by the parties and their respective successors and permitted assigns. 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  

 11 

	22.	APPROVALS 

  
 When this Agreement requires the approval of one or all of the parties to this Agreement, each and every such approval sought will not be unreasonably
withheld by the party required to provide its approval. 
  

	23.	RELATIONSHIP OF THE PARTIES 

  
 Neither party has any ownership interest in the other and their relationship, as established by this Agreement, is that of agent and master within the
confines of the terms of this Agreement. Other than the explicit and limited agency described herein, this Agreement does not create any partnership, joint venture or similar business relationship between the parties. Notwithstanding the limited
agency created hereunder, each party shall remain fully responsible for all actions of, and costs incurred by, its Related Parties not specifically related to this Agreement and the performance of obligations hereunder. 
  
 IN WITNESS WHEREOF, the parties have had a duly authorized officer,
partner or principal execute this Commercial Outsourcing Services Agreement as of the Effective Date. 
  

							
	AUXILIUM PHARMACEUTICALS, INC.	  	INTEGRATED
COMMERCIALIZATION SOLUTIONS,
INC.
				
	By:	 	 /s/    Cornelius Lansing

	  	By:	  	 /s/    Andrew Gellman

	Name:	 	Cornelius Lansing	  	Name:	  	Andrew Gellman
	Title:	 	CFO	  	Title:	  	Vice President & General Manager
		
	160 W. Germantown Pike, Suite D-5
Norristown, PA 19401
Attn:   Cornelius Lansing
Tel.:     610-239-1482
Fax:     610-279-8205	  	4006 Beltline Road, Suite 115
Addison, Texas 75001
Attn:   Vice
President & General Manager
Tel:     (972) 490-2000
Fax:     (972) 387-8286
		
	with a copy to:
General Counsel	  	with a copy to:
AmerisourceBergen Corporation
1300 Morris Drive
Chesterbrook, PA 19087
Attn:   General Counsel
Fax:     (610)
727-3612

  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  

 12 

 APPENDIX A 
  

“Act” means the Federal Food, Drug and Cosmetic Act, Title 21, United States Code, as amended, and the regulations promulgated thereunder. 

 
 “Confidential Information” means information or data (including data
owned by a party pursuant to Section 11 hereof) considered confidential by the party owning such information, whether visual, oral, electronic or in written form, including without limitation, any trade secrets, ideas, inventions or research and
development information; information related to technology, know-how, engineering or other data, processes or techniques; manufacturing, planning or marketing information, procedures or strategies or any financial or other business information of
the disclosing party and/or its Related Parties, and Product Data and data owned by a party pursuant to Sections 8 and 11 hereof. Confidential Information does not include (1) information which is or becomes public without the fault or participation
of the other party to this Agreement or which is responsive to legal process or obligation; provided, that, the receiving party promptly notifies the disclosing party of any legally required disclosure, seeks to minimize such disclosure to the
extent legally permissible and seeks confidential treatment of such required disclosure, (2) any information lawfully in the receiving party’s possession prior to the date the receiving party receives the disclosing party’s information, or
(3) any information which either party receives from a third party who rightfully possesses such information and does not have an obligation of confidentiality to the other party in connection with such information. 
  
 “Drug” shall have the meaning as set forth in Section 321(g)(1) of the Act.

  
 “Governmental Authority” shall mean any nation or government,
any state or other political subdivision thereof, or any entity exercising executive, legislative, judicial, regulatory or administrative functions of or pertaining to government. 
  
 “NDA” means a New Drug Application as defined in and contemplated by the Act. 
  
 “Person” or “Persons” means any corporation, natural
person, firm, joint venture, partnership, trust, unincorporated organization, government or any department or agency of any government. 
  
 “Products” means those products set forth in Schedule “A”, as licensed for commercial sale under all Requirements of Law. 
  
 “Related Parties” shall mean the subsidiaries, parents, affiliated
companies, officers, directors, employees, representatives, shareholders, trustees and agents of any Person. 
  
 “Requirement(s) of Law” means any law (including, without limitation, consumer law), treaty, rule or regulation or a final and binding determination of a court or other Governmental Authority, in each
case applicable to or binding upon such Person or any of its property or to which such Person or any of its property is subject. 
  
 “SEC” means the Securities and Exchange Commission. 
  
 “Taxes” shall mean any and all liabilities, losses, expenses, and costs of any kind whatsoever that are, or are in the nature of taxes, fees, or other
governmental charges, including interest, 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  

 13 

 penalties, fines and additions to tax imposed by any Federal, state or local government or taxing authority in the United
States on or with respect to: (a) the Agreement or any related agreements or any future amendment, supplement, waiver, or consent requested by Company or any required by the Agreement with respect to the execution, delivery or performance of any
thereof, or the issuance, acquisition or subsequent transfer thereof, (b) the return, acquisition, transfer of title, storage, removal, replacement, substitution, purchase, acceptance, possession, rejection, ownership, delivery, non-delivery, use,
operation, sale, abandonment, redelivery or other disposition of any interest in the Products or any part thereof, (c) the receipts or earnings arising from any interest in the Products or any part thereof, (d) any payment made pursuant to this
Agreement or to any of the Products, or (e) otherwise as a result of or by reason of the transactions contemplated by this Agreement, excluding, however, taxes imposed upon Service Provider that are based upon or measured by gross or net income and
any franchise Taxes of Service Provider or any personal property taxes for Products or equipment owned by Service Provider. 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  

 14 

 SCHEDULE A 
  

COMPANY PRODUCTS 
  

			
	 DESCRIPTION

	 	 NDC NUMBER

	TestimTM 1% (testosterone gel) CIII	 	66887-001-05

  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  

 15 

 SCHEDULE B Fee Schedule 
  

					
	 Prices per Order

	  	 Interval

	  	 Fee

	 Distribution
	  	Per Shipment	  	$[**]
	 Customer service (OMS)
	  	Per Order	  	$[**]
	 Accounts Receivable
	  	Per Invoice	  	$[**]
			
	 Total Order Costs (Assumes no backorders or split shipments)
	  	 	  	$[**]
			
	 Service Items
	  	 	  	 
			
	 Development Fee
	  	 	  	$[**]
			
	 Monthly Management and Consulting Fee
	  	 	  	$[**]
	  ̈Customer Service
  ̈Finance and Accounts Receivables
  ̈Information Technology
  ̈Distribution
  ̈Consulting
	  	 $[**]
 $[**]
 $[**]
 $[**]
 $[**]
	  	 
	 Returns
	  	Per Return	  	$[**]
	 Distribution for extra lines per Order
	  	Per Line	  	$[**]
	 Controlled Storage
	  	Per Pallet Per Month	  	$[**]
	 Chargeback Management Fee
	  	Per Month	  	$[**]
	 Chargeback Processing Fee (Manual)
	  	Per Line Processed	  	$[**]
	 Chargeback Processing Fee (Electronic)
	  	Per Line Processed	  	$[**]
			
	 Freight
	  	 	  	 
	 r Product Shipment Freight Additional Items
	  	Cost + [**]%	  	 
	 Additional Items
	  	 	  	 
	 r Product Destruction
	  	Cost + [**]%	  	 
	 r Printing of program materials (if applicable)
	  	Cost + [**]%	  	 
	 r After Cut-Off Hour shipments
	  	$[**]/shipment additional	  	 
	 r Emergency shipments
	  	$[**]/shipment additional	  	 
	 r Telecomm, facsimile and photocopies
	  	Cost + [**]%	  	 
	 r FedEx/UPS/Postage Expense
	  	Cost + [**]%	  	 
	 r Dedicated ICS travel
	  	Travel cost + employee rate	  	 
	 O Pre-approval required from Auxilium
	  	 	  	 
	 r Specialized Report Creation Fees – ERP
	  	$[**]/hr.	  	 
	 r Customized Programming
	  	$[**]/hr	  	 
	 r Pre-Approved Assessorial Labor Charge
	  	 	  	 
	 O Warehouse
	  	$[**] per hour	  	 
	 O QC, management
	  	$[**] – [**] per hour	  	 
	 r Reporting for Medicaid
	  	$[**] per quarter	  	 

  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  

 16 

 SCHEDULE C 
  

									
	 Tier One Reports

	  	 In Use
 Yes/No

	  	 Tier Two Reports

	  	 In Use
 Yes/No

	  	 Tier Three Reports

	ERP Generated	  	 	  	ERP Queries	  	 	  	 
	System generated on demand	  	 	  	Available Daily, Weekly, Monthly client specific	  	 
	 Distribution
	  	 	  	Sales	  	 	  	 
	Lot File List	  	 	  	Sales By Product	  	 	  	Flash Report
	Product File List	  	 	  	Sales By Customer	  	 	  	Sales By Territory
	Product Note File List	  	 	  	Sales by Territory/Region	  	 	  	 
	Order Structure File List	  	 	  	Sales By Order Type	  	 	  	 
	Assortment File List	  	 	  	MTD/QTD/YTD Sales by Customer	  	 	  	 
	Purchase Order Control List	  	 	  	 	  	 	  	 
	Purchase Order File List	  	 	  	Credits/Returns/Chargebacks	  	 	  	 
	Name File List	  	 	  	Credits	  	 	  	 
	Contract File List	  	 	  	Returns Register	  	 	  	 
	Customer Discount File List	  	 	  	Chargebacks	  	 	  	 
	Supplier Discount File List	  	 	  	 	  	 	  	 
	Invoice Journal	  	 	  	Inventory	  	 	  	 
	Cash Sales Journal	  	 	  	Inventory Report (Snapshot)	  	 	  	 
	Inventory Transaction List	  	 	  	 	  	 	  	 
	Stock on Hand List	  	 	  	 	  	 	  	 
	 	  	 	  	Inventory Transaction Report	  	 	  	 
	Financials	  	 	  	 	  	 	  	 
	A/P Transaction List	  	 	  	Financials	  	 	  	 
	A/P Balance List	  	 	  	Invoice Register (RW Report)	  	 	  	 
	A/P Analysis List	  	 	  	Trial Balance (RW Report)	  	 	  	 
	A/P Reconciliation List	  	 	  	Aging Report (RW Report)	  	 	  	 
	A/P Payment Statistics List	  	 	  	Cash Receipts (RW Report)	  	 	  	 
	A/R Transaction List	  	 	  	 	  	 	  	 
	A/R Balance List	  	 	  	 	  	 	  	 
	A/R Analysis List	  	 	  	 	  	 	  	 
	A/R Reconciliation List	  	 	  	 	  	 	  	 
	A/R Payment Statistics List	  	 	  	 	  	 	  	 
	A/R Aging List	  	 	  	 	  	 	  	 
	General Ledger	  	 	  	 	  	 	  	 
	G/L Transaction List	  	 	  	 	  	 	  	 
	Voucher Number Control List	  	 	  	 	  	 	  	 
	Journal Number Control List	  	 	  	 	  	 	  	 
	G/L Transaction Log File List	  	 	  	 	  	 	  	 

  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  

 17 

 EXHIBIT A 
  

CONTINUING GUARANTY AND INDEMNIFICATION AGREEMENT 
  
 The undersigned does hereby guarantee to AmerisourceBergen Corporation and each of its subsidiary corporations that each shipment or other delivery of any food, drugs,
devices, cosmetics, or other merchandise now or hereafter made by the undersigned, its subsidiaries, divisions or affiliated companies to or on the order of AmerisourceBergen Corporation or any of its subsidiaries will not be, at the time such
shipment or delivery, adulterated, misbranded, or otherwise prohibited within the meaning of the Federal Food, Drug and Cosmetic Act, 21 U.S.C.A. §301 et seq., as amended, and in effect at the time of said shipment or delivery (the Act) or
within the meaning of any applicable state or municipal law in which the definition of adulteration or misbranding are substantially the same as those contained in the Act; and such merchandise is not, at the time of such shipment or delivery,
merchandise which may not be introduced or delivered for introduction into interstate commerce under the provisions of sections 301, 404 or 505 of the Act (21 U.S.C.A. §331, §344 and §355); and such merchandise is merchandise which
may be legally transported or sold under the provisions of any other applicable federal, state, or municipal law; and the undersigned guarantees further that only those chemicals or sprays approved by federal, state or municipal authorities have
been used, and any residue in excess of the amount allowed by any such authorities has been removed therefrom. 
  
 The undersigned hereby agrees to defend, indemnify and hold AmerisourceBergen Corporation and each of its subsidiaries harmless against any and all claims, losses, damages, and liabilities whatsoever (and expenses
connected therewith, including counsel fees), arising as a result of (a) any actual or asserted violation(s) of the Act or any other federal, state or local law or regulation by virtue of which products or merchandise sold, supplied, or delivered by
the undersigned shall be alleged or determined to be adulterated, misbranded, mislabeled or otherwise not in full compliance with or in contravention of any federal, state or local law or regulation, (b) the possession, distribution, sale and/or use
of, or by reason of the seizure of, any of the undersigned’s products, including claims of bodily injury, death or property damage, and (c) any actual or asserted claim that the undersigned’s products or merchandise infringe any
proprietary or intellectual property rights of any person, including without limitation the infringement of any trademarks or service names, trade names, trade secrets, inventions, patents or the violation of any copyright laws or any other
applicable federal, state or local laws; provided, however, the undersigned shall have no indemnification or defense obligations hereunder to the extent any claim was caused by or arose out of the negligent or intentional act or omission of
AmerisourceBergen Corporation or its subsidiary corporations. The undersigned further agrees to maintain primary and noncontributing Products Liability Insurance of not less than $5,000,000.00 per occurrence, Combined Single Limit (Bodily Injury and
Property Damage) including AmerisourceBergen Corporation and its subsidiary corporations as Additional Insureds, including a Broad Form Vendors Endorsement, with provision for at least 30 days’ prior written notice to the additional insured in
the event of cancellation or material reduction of coverage, and upon request promptly submit satisfactory evidence of such insurance. All insurance coverage must be with insurance carriers having a Best’s Rating of A VII or otherwise as
reasonably approved by Service Provider. The provisions set forth herein are in addition to, and not in lieu of, any terms set forth in any purchase orders accepted by the undersigned or any separate agreement entered into between AmerisourceBergen
Corporation or any of its subsidiaries and the undersigned or any of its affiliates. In the event of any conflict between the language of such other documents and the language set forth herein, the language herein shall be controlling. 

 

									
	Auxilium Pharmaceuticals, Inc.	 	  	 	 	 	/s/    Cornelius H. Lansing II        	 	1/17/03
	Guarantor (Company Name)	 	 	 	 	 	Signature of Authorized Officer	 	Date
	 	 	 	 	 	 	 Cornelius H. Lansing II, CFO, EVP Commercial Logistics

	 	 	 	 	 	 	Name and Title	 	 
	 	 	 	 	 	 	160 W. Germantown Pike, Suite D-5, Norristown, PA 19401
	 	 	 	 	 	 	Address of Company	 	 
	 	 	 	 	 	 	(610) 239-1482
	 	 	 	 	 	 	Phone	 	 

  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  

 18 

 EXHIBIT B 
  

INTEGRATED ACCESS CENTER 
  
 The Company hereby engages Service Provider, as its agent, to develop, operate and maintain an Integrated Access Center (“Access Center”) to manage the
comprehensive distribution Services related to the Products described herein (“Access Center Services”) for the Company. Service Provider agrees to develop the Access Center and provide the Access Center Services for the fee listed in
Schedule B attached hereto and by this reference made a part hereof. The Access Center shall comprise the following: (a) a fully-integrated telecommunications and information system that will capture and manage key data from each customer requesting
information or specific services relating to the Products, (b) a toll-free Company-dedicated telephone and fax number, (c) the capability to handle queries about the Products related to order processing and account management, (d) the capability to
handle queries about clinical information regarding the Products and (e) the processing of invoices for the Products on behalf of the Company. 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  

 19 

 EXHIBIT C 
  

ORDER PROCESS MANAGEMENT 
  
 Service Provider will hire, train and manage appropriate staff personnel to provide, operate and maintain, as the Company’s agent, the Access Center. Service
Provider will obtain a dedicated toll free inbound telephone number solely for the Access Center. The responsibilities of the personnel hired in the Access Center will be to: (a) receive orders via Electronic Data Interchange (“EDI”),
facsimiles, mail or telephone, and (b) be available from 7:00 a.m. to 6:00 p.m. (central standard or daylight savings time as appropriate) to receive orders or triage calls to the Company as necessary. Service Provider shall generate and issue
invoices for the sale of the Products sold hereunder. Company invoices shall be generated. Service Provider shall manage the process of issuing Product return authorizations and Product destruction authorizations and shall coordinate the shipment of
such Products from time to time at the Company’s sole cost and expense. Service Provider shall set up customer accounts for persons and entities eligible to purchase from the Company. The Company shall periodically supply Service Provider with
its written criteria, as may be amended from time to time, for all customer eligibility. At the Company’s prior written request and subject to reasonable charges related thereto, Service Provider shall verify that such customers meet the
Company’s eligibility criteria by: (a) credit verification and establishment of credit limits, (b) license verification; and (c) account maintenance. 
  
 CUSTOMER SERVICE 
  

			
	 AVERAGE DAILY SERVICE STANDARD

	  	 PERFORMANCE GUARANTEE

	At least [**]% of orders for Products will be processed within 1 business day of receipt	  	$[**] per month where standard not met
	Order entry error rate of less [**]%	  	$[**] per month where standard not met
	At least [**]% service level to calls answered within 20 seconds	  	$[**] per month where standard not met

  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  

 20 

 EXHIBIT D 
  

WAREHOUSING AND INVENTORY PROGRAM SERVICE DESCRIPTION 
  
 Warehousing. Service Provider will warehouse and inventory Product at Service Provider’s distribution facility currently located in Louisville, Kentucky (the
“Service Provider Facility”). Company shall pay all costs, charges, expenses and import duties, if any, for delivery and transportation of all Product to and from the Service Provider Facility. Service Provider will visually inspect each
shipment of Product for external container or package damage or loss in transit (based upon records provided to Service Provider from Company). Service Provider shall notify Company when damage or loss has occurred promptly upon such discovery by
Service Provider. Service Provider will quarantine Product upon receipt and will release Product within twenty-four (24) hours of written authorization from Company. Service Provider will store all Product in compliance with good manufacturing
practice guidelines and other requirements of the U.S. Food and Drug Administration (the “FDA”) and in accordance with Company’s instructions, if any. Upon Company’s written request, Service Provider will provide disaster-relief
storage for Product at a facility of AmerisourceBergen Drug Corporation for the fees to be agreed upon between the parties in accordance with the Disaster Recovery Storage and Distribution Plan to be developed by Service Provider and delivered to
Company under separate cover letter. 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  

 21 

 EXHIBIT E 
  

DISTRIBUTION SERVICE DESCRIPTION 
  
 1.1 Company shall supply to Service Provider such quantities of Product as necessary for Service Provider to perform hereunder. Service Provider shall
distribute Product in accordance with good manufacturing practice guidelines and other requirements of the U.S. Food & Drug Administration (“FDA”), Company’s instructions, if any, and the following terms: 
  
 1.1.1. Product will be distributed by regulatory-compliant
shippers; 
  
 1.1.2. Product will be shipped
promptly upon receipt of the order transmission from Service Provider’s customer service; 
  
 1.1.3. VA and other government orders will be shipped direct or to the designated PPV (Preferred Pharmaceutical Vendor); 
  
 1.1.4. Bulk shipments will be distributed by a designated
carrier using carrier bulk shipment terms; 
  
 1.1.5. Product will be distributed on a FEFO (first expired/first out) basis unless otherwise directed by Company; 
  
 1.1.6. At the prior written request of Company, Product will be delivered as a drop ship to the customer and billed to the designated
wholesaler; 
  
 1.1.7. Orders received by
standard warehouse hours of shipping (M-F 8:00 a.m. to 3:00 p.m. EST) will be filled the same day. Orders received after this agreed upon cut-off time will be processed no later than the next business day. 
  
 1.1.8. Company may designate a specific order or orders to
be processed and shipped the same day depending on the Service Provider’s ability to perform based upon time, Service Provider personnel, and transportation carrier availability. After cut-off Company designated orders shall be subject to an
additional fee as set forth on Schedule B attached hereto and incorporated herein by this reference. 
  
 1.1.9. Emergency Shipments are defined as any order received outside of scheduled working hours (M-F 8:00 a.m. to 5:00 p.m. EST) requiring
Service Provider staff to return to the distribution center to process the order within the same day. Such Emergency Shipments shall be subject to an additional fee as set forth on Schedule B attached hereto and incorporated herein by this
reference. 
  
 1.1.10. All transportation costs
will be billed to Company at the rates set forth on Schedule B. 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  

 22 

 1.2 Distribution Functions. Service Provider shall be responsible for the following distribution and
inventory tasks: 
  
 1.2.1. To receive Product
from Company or a Company designee; 
  
 1.2.2. To
continually maintain Product inventory in accordance with the terms of this Agreement. End of lot discrepancies evidenced by a difference in physical to book inventory as noted during product distribution will trigger inventory counts and
reconciliation by Service Provider to verify and determine the cause for the discrepancy where possible; 
  
 1.2.3. To provide Company, at the Service Provider’s expense, one (1) physical product inventory per calendar year. Additional
physical product inventories including any routine cycle count programs, are chargeable based on assessorial labor charges as set forth on Schedule B. A physical inventory will be scheduled based upon a written request from Company and a
mutually agreed upon inventory date; 
  
 1.2.4.
Service Provider will allow Company, at Company’s expense the right to inspect Product at the Service Provider’s facility as long as Company provides reasonable prior written notice to Service Provider and so long as Company does not
interfere with Service Provider’s operations; provided however, for purposes of site visits and inspections related to a QA Audit, at least ten (10) business days’ prior written notice must be given; 
  
 1.2.5. To provide any required packaging materials for
distribution; 
  
 1.2.6. To pay all labor costs
for warehouse personnel; 
  
 1.2.7. To provide
computerized tracking of all shipments; 
  
 1.2.8. To pay for all security costs for the Service Provider Facility and all other warehouse locations where Product will be stored; 
  
 1.2.9. Returns will be processed within 30 days of receipt at the Service Provider facility unless a longer period of time is directed by
the Company. Returns will be processed by Service Provider on a fee basis as provided in Schedule B. 
  
 1.2.10. To ship outdated/damaged Product to a site reasonably designated by Company for disposal. All transportation and destruction costs
to be borne by Company. 
  
 1.3 Product Lost/Damaged.
Company will at all times retain title to all Product under this Agreement. Service Provider shall not be obligated to and will not insure Product against loss in shipment, damage or natural catastrophes, acts of God or other reasons of force
majeure. 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  

 23 

 EXHIBIT H 
  

CONTRACT MANAGEMENT AND CHARGEBACKS 
  
 1.1 Contract Management. For the fees listed in Schedule B, Service Provider shall, using Service Provider’s integrated bid and
contract modules, capture key demographic information and pricing arrangements negotiated between Company and its key government contract accounts, including DOD, VA and Medicaid. Service Provider will assist Company in managing such accounts,
including monitoring monthly cumulative sales, calculating applicable rebates and chargebacks based on such sales information and contract rates for each such account. Service Provider will invoice Company for rebates to be paid by Company on a
monthly basis. Service Provider will also provide to Company reports, in a format agreed upon by the parties, including pricing information for AMP and FAMP reports, and which otherwise allow Company to monitor purchasing activity by its key
accounts. 
  
 1.2 Chargeback/Rebate Indemnity. Company
hereby agrees to indemnify and hold Service Provider and its Related Parties harmless from and against any and all losses, costs and expenses (including without limitation reasonable attorneys’ fees) that Service Provider and/or its Related
Parties (as defined in Appendix A of this Agreement) suffer directly or indirectly out of any miscalculation of, or error in determination of eligibility for, any chargebacks or rebates pursuant to this Agreement. 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  

 24 

 EXHIBIT I 
  

ACCOUNTS RECEIVABLE MANAGEMENT AND CASH APPLICATIONS 
  
 Service Provider shall manage all accounts receivable transactions related to the Company managed distribution program for Product. Company will establish
a lock box at a financial institution of its choosing. Payments from customers of the Company will be directed to the address of the lock box. Financial institution will sweep the lock box daily and deposit payments into Company’s operating
account. Financial institution will forward copies of all payment transactions to Service Provider for cash application purposes. Service Provider and Company will jointly determine the following: 
  

	 	•	Credit policy 

  

	 	•	Class of trade designations 

  

	 	•	Terms and conditions 

  

	 	•	License requirements 

  

	 	•	Dunning process for past due accounts 

  

	 	•	Reporting requirements 

  
 Service Provider shall provide comprehensive accounts receivable management services in conformance with Service Provider SOPs and the Company’s
collection policies as they apply to: 
  

	 	•	Invoicing (prepare and mail customer invoices) 

  

	 	•	Cash application 

  

	 	•	Reconciliation of daily lock box deposits 

  

	 	•	Credit hold/release processing 

  

	 	•	Change to customer credit limits per Company’s approval 

  

	 	•	Credit reports (TRW and D & B) 

  

	 	•	Return authorization credits 

  

	 	•	Credit and re-bills 

  

	 	•	Reconciliation of accounts receivable to chargebacks 

  
 Service Provider shall adhere to state and federally mandated good credit and collection practices established jointly by Service Provider and Company
such as: 
  

	 	•	On-line details of calls 

  

	 	•	Call list of past due invoices 

  

	 	•	Past due reminder letters 

  

	 	•	Research and collection of unauthorized deductions 

  

	 	•	Company approved write-offs 

  
 ACCOUNTS RECEIVABLE MANAGEMENT AND CASH APPLICATIONS 
  

			
	 AVERAGE DAILY SERVICE STANDARD

	 	 PERFORMANCE GUARANTEE

	At least [**]% of cash received is posted within 2 business days of receipt	 	$[**] per month where standard not met

  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  

 25 

 EXHIBIT J 
  

FINANCIAL MANAGEMENT 
  
 Service Provider shall provide monthly reconciliation of all financial transactions related to the Company managed distribution program for Product as
follows: 
  

	 	•	Month end close 

  

	 	•	Reconciliation of cash, cash discounts and accounts receivable 

  

	 	•	Inventory roll over 

  

	 	•	Reconciliation of inventory adjustments 

  

	 	•	Reconciliation of goods received 

  

	 	•	Reconciliation of sales and cost of goods sold 

  

	 	•	Reconciliation of returns and cost of goods returns 

  
 Service Provider will provide on a monthly basis or such frequency as mutually agreed upon with the Company the following financial reports: 

 

	 	•	Trial Balance 

  

	 	•	Cash Application Summary 

  

	 	•	Accounts Receivable Reports 

  

	 	•	Inventory Reports 

  

	 	•	Sales Reports 

  

	 	•	Cash Discounts Report 

  
 FINANCIAL SUPPORT AND RECONCILIATION 
  

			
	 AVERAGE DAILY SERVICE STANDARD

	 	 PERFORMANCE GUARANTEE

	Month-end close information to be provided within [**] business days of month end	 	$[**] per month where standard not met

  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  

 26 

 EXHIBIT K 
  

IT SERVICE DESCRIPTION 
  
 1.1 Date Management and Reporting. For the fees listed in Schedule B - ERP, Service Provider shall provide Company with the standard daily,
weekly and/or monthly sales and management reports listed on Schedule C, attached hereto and incorporated herein by this reference, or in a standard electronic form. These standard reports shall be provided by EDI transmission or any other
method agreed upon by the parties from time to time, and shall contain the following information: (a) sales by customer and customer zip code, (b) returned Products, (c) inventory at Service Provider’s Facility, and (d) damaged or destroyed
Products. Company and Service Provider shall jointly and reasonably determine the data elements and formats as well as the frequency of all such reports for non-standard reporting. Although mutually agreed-upon standard reports are included in the
pricing provided under this Agreement, there will be additional charges for special reports based upon programming charges as listed in Schedule B — Specialized Report Fees. Company will be responsible for hardware or software costs
directly and/or for the fees listed in Schedule B. 
  
 1.2
On-line Access. For the fees listed in Schedule B, Service Provider shall provide Company with access to the ERP system. Company may access system via dial-up, frame relay or virtual private network (VPN). Company will be responsible
for hardware, software, or telecommunication costs either directly and/or for the fees listed in Schedule B. 
  
 1.3 Service Provider has in place disaster-relief plans consisting of Disaster Recovery Procedures, Alternative Distribution Center Operation Procedures,
Telecommunications Switch Over During Disaster or Emergency Period, and AS/400 System Switch Over During Disaster or Emergency Period (collectively referred to as the “Disaster Plans”), all of which Service Provider has delivered to
Company under separate cover. Service Provider commits to maintaining the Disaster Plans in effect for the entire Term of the Agreement, providing disaster-relief storage for Product in accordance with the Disaster Procedures, and otherwise
implementing the Disaster Procedures should the need arise at any time during the Term of the Agreement. 
  
 INFORMATION TECHNOLOGY SERVICE DESCRIPTION 
  

			
	 AVERAGE DAILY SERVICE STANDARD

	 	 PERFORMANCE GUARANTEE

	Systems down time less than [**]% per month, excluding scheduled maintenance	 	$[**] per month where standard not met

  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  

 27

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00068-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00068-of-00352.parquet"}]]